Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Sofosbuvir + GS-5816 Versus Sofosbuvir + Ribavirin in Chronic Hepatitis C
2014-001682-27Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic hepatitis C (CHC) comparing Sofosbuvir + GS-5816 fixed-dose combination with Sofosbuvir + ribavirin (2 arms). Primary endpoint: SVR12. Started Jun 2014; status: completed.
02
Drugs
sofosbuvirvelpatasvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-001682-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001682-27.